Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Holdings Raised by Quantinno Capital Management LP

Quantinno Capital Management LP grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,191 shares of the biotechnology company’s stock after acquiring an additional 5,482 shares during the period. Quantinno Capital Management LP’s holdings in Ironwood Pharmaceuticals were worth $79,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IRWD. KBC Group NV grew its stake in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares in the last quarter. CWM LLC grew its stake in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares in the last quarter. Diversified Trust Co acquired a new position in Ironwood Pharmaceuticals in the third quarter worth approximately $52,000. Legacy Capital Group California Inc. bought a new position in Ironwood Pharmaceuticals during the third quarter valued at approximately $59,000. Finally, First Dallas Securities Inc. acquired a new stake in Ironwood Pharmaceuticals in the second quarter valued at approximately $73,000.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 12.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective on the stock. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.40.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $3.53 on Wednesday. The firm has a market cap of $564.90 million, a price-to-earnings ratio of -117.67 and a beta of 0.41. The firm has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $4.95. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The business had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Ironwood Pharmaceuticals’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.12 EPS. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.